Clinical Chemistry - McMaster Experts

publication venue for

A Multimarker approach for the prediction of evolving myocardial injury in women presenting with symptoms suggestive of acute coronary syndromes 2009
A biomarker panel for identification of acute coronary syndrome patients at risk for subsequent heart failure/death 2009
A mass spectrometry approach to identify surrogate biomarkers; for early responders to an anti-metastatic/anti-tumor investigational agent 2009
Cytokines and cell adhesion molecules exhibit cancer specific profiles in patients with metastatic disease treated with an investigational anti-metastatic agent 2009
Evaluation of whole blood ketone meter for measuring low levels of BHB in fasting adults 2009
Impact of "change criteria" and a novel high sensitivity cardiac troponin I assay in predicting health outcomes 2009
Long-term survival is predicted in patients presenting with chest pain by PAPP-A measurements 2009
Method validation study to evaluate the analytical performance of the STAT-Site meter for the measurement of serum Beta-Hydroxybutyrate concentration 2009
Pediatric critical values: pediatricians' opinions 2009
Simplified Quantification of Immunohistochemical Staining Based on Measurement of Color Coordinates in a Pre-Defined Pattern 2009
The Ordering Patterns of Serological Tests in the Diagnosis of Celiac Disease 2009
The utility of Troponin T to the diagnosis of silent myocardial infarction in patients submitted to noncardiac surgery - preliminary results of the VISION Study 2009
Evaluation of a high sensitivity cardiac troponin I assay in an Acute Coronary Syndrome population 2008
Preliminary investigation of a high sensitivity PAPP-A research assay in an Acute Coronary Syndrome population 2008
A fast, non-invasive method for measurement of cholesterol in skin samples. 2007
Early detection of rising patterns of troponin I, T and NT-proBNP in a chest pain emergency department cohort 2007
Serial cytokine profile in an emergency department chest pain population 2007
A microwell-based galactose oxidase-Schiff's assay for Thomsen-Friedenreich antigen in diagnosis of lung cancer 2006
Comparing the World Health Organization MONICA definition for Acute Myocardial Infarction versus the ESC/ACC definition in identifying chest pain patients at increased risks 2006
A novel, non-invasive skin-stripping device and method for measurement of cholesterol in skin samples. 2005
A short-interval specimen collection protocol with early accurate detection of acute myocardial infarction using the sensitive AccuTnI biomarker 2005
An evaluation of a new blood test for TB (M-tuberculosis) detection in patients receiving BCG (Bacillus Calmette-Guerin) therapy 2005
Assessing the requirement for the six-hour interval between specimens in the American Heart Association case definition for AMI, using a highly sensitive troponin assay 2005
Biomarker case study applying the 2003 AHA case definition for AMI in epidemiology and clinical research studies with the AccuTnI marker 2005
Clinical utility of biochemical markers in the diagnosis and risk stratification of stroke patients presenting to the emergency department within 3 hours of symptom onset 2005
Clinical utility of highly sensitive assays for biochemical markers of traumatic brain injury in the emergency department: a prospective case-control study 2005
Effects on rounding on quality control 2005
Evaluating albumin depletion from human serum using a ProteoSpin (TM) column 2005
Identification of novel biomarkers of neuropsychiatric systemic lupus erythematosus 2005
Performance of CKMB isoforms in a population defined by the 2003 American Heart Association case definition for acute coronary heart disease 2005
Quantitative measurement of urinary glycosaminoglycans using alcian blue dot blot assay for diagnosis of mucopolysaccharidoses 2005
Clinical evaluation of the Beckman Coulter AccuTnI assay for the early detection of acute myocardial infarction 2004
Comparison of the albumin cobalt binding test for ischemia modified albumin: Field testing versus reference method 2004
Impact of the evolving definition of myocardial infarction and the improved analytical sensitivity of troponin measurement on the frequency of diagnosis 2004
Investigation of an objective spectrophotometric assessment for turbidity on the aeroset analyser according to CLIA '88. 2003
Performance of the Abbott PCx glucometer in the neonatal intensive care unit. 2003
Application of a quality control plan for automated chemistry using a single rule by analyte control process. 2002
Applying proteomics to characterize the plasma protein profile correlating to hyperhomocysteinemia: Linking genomics and proteomics. 2001
Prognostic use of cardiac troponin T and troponin I in patients with heart failure. 2001
Spuriously high FT4 is associated with HAMA in pediatric but not adult samples. 2001
Comparison of ColorectAlert to fecal occult blood testing and carcinoembryonic antigen for colorectal cancer screening. 2000
Determination of pepsinogen C concentration in breast tumor cytosols by a highly sensitive immunofluorometric assay and its association with ether prognostic variables. 1999
ELISA-determined p21(WAF1) expression does not correlate with non-small cell lung cancer aggressiveness. 1999
Use of skin cholesterol to monitor response to cholesterol-lowering therapy. 1999
Detection of spuriously high free thyroxine results in pediatric patients. 1998
Hyperhomocysteinemia and mutations in methylene tetrahydrofolate reductase in individuals with early coronary artery disease. 1998
Prognostic significance of quantitatively-analyzed p53 protein accumulation in lung carcinoma. 1998
Evaluation of HemogloBind™ for Removal of o-Raffinose Cross-Linked Hemoglobin (Hemolink™) from Serum 1997
Comparison of 3 assays for the measurement of activated protein C resistance (APCR). 1997
ELISA-detected p53 protein accumulation is a prognostic factor in a large cohort of breast cancer patients. 1997
Frequency of prostate specific antigen mRNA expression in lung tumors. 1997
Arylsulfatase A pseudodeficiency and the dopamine receptor D4 polymorphism: Genetic risk factors for psychiatric disorders in Caucasians. 1996
Associations between PSA and IGF-I, IGF-II, IGFBP-1, and IGFBP-3 in breast cancer. 1996
Comparison of immunofluorometry and immunohistochemistry for the detection of p53 protein in lung cancer. 1996
Mutation frequencies of cholesterol ester transfer protein (CETP) and hepatic lipase (HL) in a north American population. 1996
P53 protein is absent from the serum of patients with lung cancer. 1996
Proficiency testing of hemoglobin A1c (HbA1c) in the province of Ontario, Canada. 1996
Proficiency testing of hemoglobin A1c (HbA1c) in the province of Ontario, Canada. 1996
EXPRESSION OF THE PROSTATE-SPECIFIC ANTIGEN GENE IN A PRIMARY OVARIAN-CARCINOMA 1995
IMMUNOFLUOROMETRICALLY QUANTIFIED P53 PROTEIN AS A PROGNOSTIC INDICATOR IN OVARIAN-CARCINOMA 1995
QUANTITATIVE-ANALYSIS OF MUTANT P53 PROTEIN IN BREAST-CARCINOMA - RELATIONSHIPS TO OTHER PROGNOSTIC FACTORS 1995
RAPID FORMAT ASSAY FOR THE DETECTION OF ANTISTREPTOKINASE ANTIBODY IN HUMAN BLOOD 1995
SERUM PROFILE OF MULTIPLE CARDIAC BIOCHEMICAL MARKERS IN PATIENTS PRESENTING TO THE ER WITH CHEST PAIN 1995
CHANGES IN SERUM CARNOSINASE ACTIVITY IN PATIENTS WITH THYROID-DISEASES 1990
THE EFFECT OF STORAGE ON PLASMA SAMPLES USED IN HEPARIN ASSAYS 1990
COMPARISON OF LUTEINIZING-HORMONE (LH, LUTROPIN) IMMUNOREACTIVITY IN SERUM BY RIA AND TIME-RESOLVED FLUORESCENCE - FINDINGS IN SERUM FROM NORMAL-CHILDREN AND THOSE TREATED WITH LHRH ANALOGS 1989
ADAPTATION OF DRUGS OF ABUSE ASSAYS TO A CENTRIFUGAL ANALYZER 1983
STOICHIOMETRIC APPROACH FOR DETERMINATION OF SERUM AMYLASE 1976
Determination of Clinically Acceptable Analytical Variation of Cardiac Troponin at Decision Thresholds. 70:967-977. 2024
Discordant High-Sensitivity Cardiac Troponin I Concentrations in the General Population. 70:562-564. 2024
High-Sensitivity Cardiac Troponin and the Management of Congenital Heart Disease in Newborns and Infants. 70:486-496. 2024
Reference Interval Harmonization: Harnessing the Power of Big Data Analytics to Derive Common Reference Intervals across Populations and Testing Platforms. 69:991-1008. 2023
High-sensitivity Troponin I Predicts Major Cardiovascular Events after Non-Cardiac Surgery: A Vascular Events in Non-Cardiac Surgery Patients Cohort Evaluation (VISION) Substudy. 69:492-499. 2023
The PROVE-HF Study: Additional Proof for the Inclusion of the Manufacturer’s Name When Reporting B-Type Natriuretic Peptide Results. 68:1353-1355. 2022
Analytical Considerations in Deriving 99th Percentile Upper Reference Limits for High-Sensitivity Cardiac Troponin Assays: Educational Recommendations from the IFCC Committee on Clinical Application of Cardiac Bio-Markers. 68:1022-1030. 2022
Commentary on Macrotroponin Complex as a Cause for Cardiac Troponin Increase after COVID-19 Vaccination and Infection. 68:1019-1020. 2022
The Need to Develop Clinical Guidance for the Use of High-Sensitivity Cardiac Troponin in Pediatric and Neonatal Patients. 68:884-886. 2022
Imprecision and Delta Criteria for a New ESC 0/2-Hour Algorithm. 68:721-722. 2022
Sex-Specific Absolute Delta Thresholds for High-Sensitivity Cardiac Troponin T. 68:441-449. 2022
Microbial Taxonomy: How and Why Name Changes Occur and Their Significance for (Clinical) Microbiology. 68:134-137. 2021
A Large Number of Fresh Samples and a Wide Range of Total Prostate-Specific Antigen (tPSA) Concentrations Is Important to Detect Differences in PSA Methods. 67:1155-1157. 2021
Getting Cardiac Troponin Right: Appraisal of the 2020 European Society of Cardiology Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation by the International Federation of Clinical Chemistry and Laboratory Medicine Committee on Clinical Applications of Cardiac Bio-Markers. 67:730-735. 2021
Cardiac Troponin Testing in Patients with COVID-19: A Strategy for Testing and Reporting Results. 67:107-113. 2021
Impact of Switching Sample Types for High-Sensitivity Cardiac Troponin I Assays in the 0/1 Hour Algorithms. 67:319-321. 2021
Physicians Should Obtain Perioperative Cardiac Troponin Measurements in At-Risk Patients Undergoing Noncardiac Surgery. 67:50-53. 2021
Sex-Specific Kinetics of High-Sensitivity Cardiac Troponin I and T following Symptom Onset and Early Presentation in Non-ST-Segment Elevation Myocardial Infarction. 67:321-324. 2021
Variability in Cardiac Biomarkers during Hemodialysis: A Prospective Cohort Study. 67:308-316. 2021
Commentary on A Rare Cause of Virilization, Short Stature, and Hypertension. 66:1493-1494. 2020
Lot-to-Lot Variation for Commercial High-Sensitivity Cardiac Troponin: Can We Realistically Report Down to the Assay’s Limit of Detection?. 66:1146-1149. 2020
A Three-Site Immunoassay for High-Sensitivity Cardiac Troponin I with Low Immunoreactivity for Macrocomplexes. 66:854-855. 2020
Educational Recommendations on Selected Analytical and Clinical Aspects of Natriuretic Peptides with a Focus on Heart Failure: A Report from the IFCC Committee on Clinical Applications of Cardiac Bio-Markers. 65:1221-1227. 2019
Effect of Storage Temperature for B-Type Natriuretic Peptide Concentrations for Primary Healthcare Populations. 65:811-812. 2019
Measurement of Treatment Effects Requires Instruments Responsive to Change Based on the Minimal Important Difference. 65:708-709. 2019
High-Sensitivity Generation 5 Cardiac Troponin T Sex- and Age-Specific 99th Percentiles in the CALIPER Cohort of Healthy Children and Adolescents. 65:589-591. 2019
A Mendelian Randomization-Based Approach to Identify Early and Sensitive Diagnostic Biomarkers of Disease. 65:427-436. 2019
External Quality Assessment Testing Near the Limit of Detection for High-Sensitivity Cardiac Troponin Assays. 64:1402-1404. 2018
The Power of Social Media in Medicine and Medical Education: Opportunities, Risks, and Rewards. 64:1284-1290. 2018
Clinical Laboratory Practice Recommendations for the Use of Cardiac Troponin in Acute Coronary Syndrome: Expert Opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine. 64:645-655. 2018
Comprehensive Age and Sex 99th Percentiles for a High-Sensitivity Cardiac Troponin I Assay. 64:398-399. 2018
Effect of Repeat Measurements of High-Sensitivity Cardiac Troponin on the Same Sample Using the European Society of Cardiology 0-Hour/1-Hour or 2-Hour Algorithms for Early Rule-Out and Rule-In for Myocardial Infarction. 63:1163-1165. 2017
Total Analytic Error for Low Cardiac Troponin Concentrations (≤10 ng/L) by Use of a High-Sensitivity Cardiac Troponin Assay. 63:1043-1045. 2017
Economic Considerations of Early Rule-In/Rule-Out Algorithms for The Diagnosis of Myocardial Infarction in The Emergency Department Using Cardiac Troponin and Glycemic Biomarkers. 63:593-602. 2017
Simulation Models of Misclassification Error for Single Thresholds of High-Sensitivity Cardiac Troponin I Due to Assay Bias and Imprecision. 63:585-592. 2017
Best Practices for Monitoring Cardiac Troponin in Detecting Myocardial Injury. 63:37-44. 2017
Rule-In and Rule-Out of Myocardial Infarction Using Cardiac Troponin and Glycemic Biomarkers in Patients with Symptoms Suggestive of Acute Coronary Syndrome. 63:403-414. 2017
Acceptable Analytical Variation May Exceed High-Sensitivity Cardiac Troponin I Cutoffs in Early Rule-Out and Rule-In Acute Myocardial Infarction Algorithms. 62:887-889. 2016
STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies. 61:1446-1452. 2015
Hospital Admission and Myocardial Injury Prevalence after the Clinical Introduction of a High-Sensitivity Cardiac Troponin I Assay. 61:1209-1210. 2015
Assessment of the 99th or 97.5th Percentile for Cardiac Troponin I in a Healthy Pediatric Cohort. 60:1574-1576. 2014
Proposed Regulatory Framework for Direct-to-Consumer Genetic Testing: Diagnostics vs Genetic Screening. 60:1455-1456. 2014
The Preventive Potential of Common, Easily Measured Risk Factors for Cardiovascular Disease. 60:1450-1451. 2014
State of the Art for Measurement of Urine Albumin: Comparison of Routine Measurement Procedures to Isotope Dilution Tandem Mass Spectrometry. 60:471-480. 2014
High-Sensitivity Cardiac Troponin I for Predicting Death in a Female Emergency Department Population. 60:271-273. 2014
Ninety-Minute vs 3-h Performance of High-Sensitivity Cardiac Troponin Assays for Predicting Hospitalization for Acute Coronary Syndrome. 59:1407-1410. 2013
Implications of adjustment of high-sensitivity cardiac troponin T assay. 59:574-576. 2013
Persistent Increases in Cardiac Troponin Concentrations As Measured with High-Sensitivity Assays after Acute Myocardial Infarction. 59:443-445. 2013
Cardiac and Inflammation Biomarker Profile after Initiation of Adjuvant Trastuzumab Therapy. 59:327-329. 2013
Applicability of the AGREE II Instrument in Evaluating the Development Process and Quality of Current National Academy of Clinical Biochemistry Guidelines. 58:1426-1437. 2012
Assessing Pneumatic Tube Systems with Patient-Specific Populations and Laboratory-Derived Criteria. 58:792-795. 2012
Biomarkers for Predicting Serious Cardiac Outcomes at 72 Hours in Patients Presenting Early after Chest Pain Onset with Symptoms of Acute Coronary Syndromes. 58:298-302. 2012
High-Sensitivity Cardiac Troponin Assays—Change Is Important. 58:311-313. 2012
An Alternative Approach for Detecting Interferences in Enzymatic Acetaminophen Assays. 57:1203-1204. 2011
High-Sensitivity Cardiac Troponin I Measurement for Risk Stratification in a Stable High-Risk Population. 57:1146-1153. 2011
Measurement of Hemoglobin A1c from Filter Papers for Population-Based Studies. 57:577-585. 2011
Increasing Cardiac Troponin Changes Measured by a Research High-Sensitivity Troponin I Assay: Absolute vs Percentage Changes and Long-Term Outcomes in a Chest Pain Cohort. 56:1902-1904. 2010
2007 Universal Myocardial Infarction Definition Change Criteria for Risk Stratification by Use of a High-Sensitivity Cardiac Troponin I Assay. 56:487-489. 2010
Utility of Urine Myoglobin for the Prediction of Acute Renal Failure in Patients with Suspected Rhabdomyolysis: A Systematic Review. 55:2190-2197. 2009
Short- and Long-Term Risk Stratification Using a Next-Generation, High-Sensitivity Research Cardiac Troponin I (hs-cTnI) Assay in an Emergency Department Chest Pain Population. 55:1809-1815. 2009
A Patient with a Leg Rash, Pedal Edema, Renal Failure, and Thrombocytopenia. 55:1419-1422. 2009
Getting Closer to P-Selectin. 55:1051-1052. 2009
Analytic and Clinical Utility of a Next-Generation, Highly Sensitive Cardiac Troponin I Assay for Early Detection of Myocardial Injury. 55:573-577. 2009
Current Issues in Measurement and Reporting of Urinary Albumin Excretion. 55:24-38. 2009
Population-Based Genomewide Genetic Analysis of Common Clinical Chemistry Analytes. 55:39-51. 2009
Association of the FABP2 T54 Variant with Plasma Triglycerides and Insulin Resistance in a Multiethnic Population. 54:1742-1744. 2008
Requesting and Interpreting Urine Albumin Measurements in the Primary Health Care Setting. 54:1595-1597. 2008
Is a Pattern of Increasing Biomarker Concentrations Important for Long-Term Risk Stratification in Acute Coronary Syndrome Patients Presenting Early after the Onset of Symptoms?. 54:747-751. 2008
Risk Stratification for Heart Failure and Death in an Acute Coronary Syndrome Population Using Inflammatory Cytokines and N-Terminal Pro-Brain Natriuretic Peptide. 53:2112-2118. 2007
Accuracy and Biological Variation of Human Serum Paraoxonase 1 Activity and Polymorphism (Q192R) by Kinetic Enzyme Assay. 53:310-317. 2007
Long-Term Health Outcomes Associated with Detectable Troponin I Concentrations. 53:220-227. 2007
Health Outcomes Categorized by Current and Previous Definitions of Acute Myocardial Infarction in an Unselected Cohort of Troponin-Naïve Emergency Department Patients. 52:2028-2035. 2006
Assessing the Requirement for the 6-Hour Interval between Specimens in the American Heart Association Classification of Myocardial Infarction in Epidemiology and Clinical Research Studies. 52:812-818. 2006
Diagnostic Pitfall in PCR-Based α-Thalassemia Genotyping Resulting from a (G→C) Polymorphism at Nucleotide 71 3′ to the α2-Globin Gene Termination Codon. 52:536-537. 2006
Human Kallikrein 4: Quantitative Study in Tissues and Evidence for Its Secretion into Biological Fluids. 51:1432-1442. 2005
Summarizing Studies of Diagnostic Test Performance. 49:1783-1784. 2003
Single-Tube Multiplex-PCR Screen for Anti-3.7 and Anti-4.2 α-Globin Gene Triplications. 49:1679-1682. 2003
Multiple Minisequencing Screen for Seven Southeast Asian Nondeletional α-Thalassemia Mutations. 49:800-803. 2003
Determination of Gabapentin in Plasma by Liquid Chromatography with Fluorescence Detection after Solid-Phase Extraction with a C18 Column. 48:2259-2261. 2002
The Serum S100B Concentration Is Age Dependent. 48:950-952. 2002
The serum S100B concentration is age dependent. 48:950-952. 2002
Immunoassay for Serum Glutamine Synthetase in Serum: Development, Reference Values, and Preliminary Study in Dementias. 48:375-378. 2002
Overview of Evidence-based Medicine: Challenges for Evidence-based Laboratory Medicine. 47:1536-1546. 2001
A Novel Test for the Measurement of Skin Cholesterol. 47:1302-1304. 2001
Effect of Rheumatoid Factor on Cardiac Troponin I Measurement Using Two Commercial Measurement Systems. 46:307-308. 2000
Exon 5 of the p53 gene is a target for deletions in ovarian cancer. 44:72-77. 1998
Time-resolved immunofluorometric assay of p53 protein. 41:1720-1729. 1995
Time-resolved immunofluorometric assay of p53 protein.. 41:1720-1729. 1995
Therapeutic monitoring of sertraline. 40:498-499. 1994
Is determination of creatine kinase-2 after electrophoretic separation accurate?. 40:177-183. 1994
COMPETITIVE SOLID-PHASE ENZYME-IMMUNOASSAY FOR MELATONIN IN HUMAN AND RAT SERUM AND RAT PINEAL-GLAND. 39:2322-2325. 1993
CONJUGATED, BUT NOT UNCONJUGATED, BILIRUBIN NEGATIVELY INTERFERES IN HITACHI-747 ASSAY OF INORGANIC PHOSPHORUS. 39:2345-2346. 1993
Competitive solid-phase enzyme immunoassay for melatonin in human and rat serum and rat pineal gland. 39:2322-2325. 1993
A Multicenter Evaluation of Lipid Profiling with a Compact Analyzer (Miles Clinistat). 38:1437-1439. 1992
Testing for Creatine Kinase and Creatine Kinase-2 in Ontario: Reference Ranges and Assay Types. 38:1365-1370. 1992
Proficiency testing for creatine kinase isoenzyme CK-2 (CK-MB) in Ontario. 36:2102-2105. 1990
Simplified fluorometric determination of salicylate in plasma. 36:1690-1691. 1990
ETHICS AND LABORATORY MEDICINE. 36:1404-1407. 1990
Ethics and Laboratory Medicine. 36:1404-1407. 1990
Improved sample preparation in determination of urinary metanephrines by liquid chromatography with electrochemical detection. 36:538-540. 1990
SEMI-AUTOMATED DIRECT COLORIMETRIC MEASUREMENT OF CREATINE-KINASE ISOENZYME-MB ACTIVITY AFTER EXTRACTION FROM SERUM BY USE OF A CK-MB-SPECIFIC MONOCLONAL-ANTIBODY. 34:575-581. 1988
Use of a competitive inhibitor in a kinetic enzymatic method for measuring ethanol in serum.. 33:2296-2298. 1987
Determination of unconjugated 3-methoxy-4-hydroxyphenylglycol by liquid chromatography for monitoring inhibition of monoamine oxidase activity in plasma.. 33:2078-2080. 1987
Improved separation of antigen-antibody complex in RIA involving ammonium sulfate.. 33:415-415. 1987
Stability of gastric-juice pepsin, and a method for its preservation.. 30:1582-1583. 1984
Liquid-chromatographic determination of amiodarone and its N-desethyl metabolite in plasma.. 30:1423-1424. 1984
Substrate-labeled fluorescent immunoassay for ethosuximide evaluated.. 29:1567-1568. 1983
Liquid-chromatographic determination of nadolol in plasma.. 29:1085-1087. 1983
ONLINE MEASUREMENT OF POTASSIUM IN BLOOD BY CHEMICAL-SENSITIVE FIELD-EFFECT TRANSISTORS - A PRELIMINARY-REPORT. 29:405-406. 1983
Liquid-chromatographic determination of pentobarbital in plasma with use of a resin column and an alkaline mobile phase.. 28:1772-1774. 1982
Liquid-chromatographic determination of ethylene glycol in plasma.. 28:32-33. 1982
Solid-phase radioimmunoassay with protein-A-bearing Staphylococcus aureus cells used to assay a protein (ferritin) and a hapten (digoxin).. 26:37-40. 1980
Valproic acid in plasma, as determined by liquid chromatography.. 25:1984-1985. 1979
Why measure total lactate dehydrogenase activity?. 25:1869-1869. 1979
Evaluations of the creatine kinase MB kit of Boehringer.. 25:1518-1518. 1979
Inhibition inversion in the AACC selected method for serum cholinesterase.. 25:1511-1512. 1979
Gas-chromatographic analysis for valproic acid as phenacyl esters.. 25:1303-1305. 1979
Quantitation of urinary porphyrins by use of second-derivative spectroscopy.. 25:71-74. 1979
Evaluation of the BMC column-chromatographic method for creatine kinase isoenzyme MB.. 24:519-520. 1978
Use of a programmable calculator in processing and interpreting serum cholinesterase phenotypes.. 24:223-226. 1978
Estimation of maprotiline in serum by gas-chromatography, with use of a nitrogen-specific detector.. 23:1849-1852. 1977
A Radioimmunoassay for Serum Ferritin. 23:683-689. 1977
Determination of carbamazepine in serum.. 23:616-616. 1977
Thermodynamic aspects of some radioassays.. 22:70-73. 1976
Precolumn Methylation of Phenobarbital with Trimethylanilinium Hydroxide. 21:1346-1347. 1975
Diagnosis of Heart and Liver Disease. 21:177-177. 1975
Modified Pisano Method for Estimating Urinary Metanephrines. 19:611-614. 1973
Diphenylhydantoin Interference with Spectrophotometric Barbiturate Estimations. 19:433-433. 1973
"Glycerate Dehydrogenase" Activity in Acute Myocardial Infarction and Myocardial Ischemia. 18:275-279. 1972
Prenatal Diagnosis of Genetic Disorders: Trials and Tribulations. 18:179-187. 1972
An Initial Reaction Rate Assay for "Glycerate Dehydrogenase". 17:1089-1092. 1971

Clinical Chemistry Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)